Entresto is a combination of a first-in-class neprilysin inhibitor and an angiotensin receptor blocker indicated for the treatment of heart failure with reduced ejection fraction.
Sylvester O. Agbahiwe PharmD, BCACP
Advertisement
Articles by Sylvester O. Agbahiwe PharmD, BCACP
Kcentra is the first nonactivated 4-factor prothrombin complex concentrate for the urgent reversal of acquired coagulation deficiency induced by vitamin K antagonist therapy.
Advertisement
Latest Updated Articles
- Kazano by Takeda Pharmaceuticals America, Inc
February 17th 2014
EntrestoNovember 12th 2015
Kcentra by CSL BehringApril 21st 2014
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Panel Unanimously Backs Moderna’s Breakthrough mRNA Flu Vaccine Amid Political Turbulence
2
Sonrotoclax Plus Zanubrutinib Achieves Undetectable MRD Rates Above 90% in Frontline CLL/SLL
3
ADA 2026: Lipid Management and Cardiovascular Prevention Updates for People With Diabetes
4
McKesson ideaShare 2026: How AI and Automation Are Reshaping the Dispensing Experience
5